Hessian Labs
Hessian Labs develops non-invasive, platelet-based proteomic diagnostics for cancer. The organization combines platelet proteomics, assay development, and an AI-enabled molecular informatics platform to discover and translate protein biomarkers into clinical tests for early detection, therapy monitoring, and multi-cancer screening. The company maintains a research publication record and a patent portfolio and is developing tests for prostate and breast cancer and a multi-cancer screening application.
Industries
Nr. of Employees
small (1-50)
Hessian Labs
Worcester, Massachusetts, United States, North America
Products
Platelet-proteomics prostate cancer detection test
A blood-based proteomic assay designed to indicate whether prostate cancer is likely to be present and to reduce unnecessary biopsies.
Platelet-proteomics prostate cancer monitoring test
A blood-based assay focused on identifying aggressive prostate cancer to inform whether urgent treatment is needed or active surveillance is appropriate.
Platelet-proteomics breast cancer diagnostic and monitoring tests
A suite of blood-based assays intended to classify breast lesions (invasive vs non-invasive), detect progression in genetically at-risk individuals, and monitor therapy response.
Platelet-proteomics multi-cancer screening test (development)
A multi-cancer blood screening application under development using platelet proteomic signatures to detect multiple organ-specific cancers.
Platelet-proteomics prostate cancer detection test
A blood-based proteomic assay designed to indicate whether prostate cancer is likely to be present and to reduce unnecessary biopsies.
Platelet-proteomics prostate cancer monitoring test
A blood-based assay focused on identifying aggressive prostate cancer to inform whether urgent treatment is needed or active surveillance is appropriate.
Platelet-proteomics breast cancer diagnostic and monitoring tests
A suite of blood-based assays intended to classify breast lesions (invasive vs non-invasive), detect progression in genetically at-risk individuals, and monitor therapy response.
Platelet-proteomics multi-cancer screening test (development)
A multi-cancer blood screening application under development using platelet proteomic signatures to detect multiple organ-specific cancers.
Expertise Areas
- Platelet proteomics
- Proteomic biomarker discovery and validation
- Clinical diagnostic test development
- AI-enabled molecular informatics
Key Technologies
- Platelet proteomics
- Proteomic assays
- AI-enabled molecular informatics
- Blood-based biomarker assays